Suppr超能文献

瑞德西韦和全身皮质类固醇治疗 COVID-19:贝叶斯再分析。

Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis.

机构信息

Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada; Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Department of Epidemiology, Occupational Health, and Biostatistics, McGill University, Montréal, Canada.

Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada.

出版信息

Int J Infect Dis. 2021 Mar;104:671-676. doi: 10.1016/j.ijid.2021.01.065. Epub 2021 Feb 1.

Abstract

BACKGROUND

The global death toll from coronavirus disease 2019 (COVID-19) has exceeded 2 million, and treatments to decrease mortality are needed urgently.

OBJECTIVES

To examine the probabilities of a clinically meaningful reduction in mortality for remdesivir and systemic corticosteroids.

DESIGN, SETTING AND PARTICIPANTS: This was a probabilistic re-analysis of clinical trial data for corticosteroids and remdesivir in the treatment of hospitalized patients with COVID-19 using a Bayesian random effects meta-analytic approach. Studies were identified from existing meta-analyses performed by the World Health Organization.

MAIN OUTCOMES AND MEASURES

Posterior probabilities of an absolute decrease in mortality compared with control patients, by subgroups based on oxygen requirements, were calculated for corticosteroids and remdesivir. Probabilities of ≥1%, ≥2% and ≥5% absolute decrease in mortality were quantified.

RESULTS

For patients needing mechanical ventilation, the probability of ≥1% absolute decrease in mortality was 4% for remdesivir and 93% for corticosteroids. For patients needing supplemental oxygen without mechanical ventilation, the probability of ≥1% absolute decrease in mortality was 81% for remdesivir and 93% for dexamethasone. Finally, for patients who did not need oxygen support, the probability of ≥1% absolute decrease in mortality was 29% for remdesivir and 4% for dexamethasone.

CONCLUSIONS AND RELEVANCE

Using a Bayesian analytic approach, remdesivir had low probability of achieving a clinically meaningful reduction in mortality, except for patients needing supplemental oxygen without mechanical ventilation. Corticosteroids were more promising for patients needing oxygen support, especially mechanical ventilation. While awaiting more definitive studies, this probabilistic interpretation of the evidence will help to guide treatment decisions for clinicians, as well as guideline and policy makers.

摘要

背景

全球 2019 冠状病毒病(COVID-19)死亡人数已超过 200 万,急需降低死亡率的治疗方法。

目的

研究瑞德西韦和全身皮质类固醇降低死亡率的临床意义。

设计、设置和参与者:这是使用贝叶斯随机效应荟萃分析方法对 COVID-19 住院患者皮质类固醇和瑞德西韦治疗的临床试验数据进行概率重新分析。研究从世界卫生组织进行的现有荟萃分析中确定。

主要结果和措施

根据对氧气需求的亚组,计算皮质类固醇和瑞德西韦与对照患者相比死亡率绝对降低的后验概率。量化死亡率绝对降低≥1%、≥2%和≥5%的概率。

结果

对于需要机械通气的患者,瑞德西韦的死亡率绝对降低≥1%的概率为 4%,皮质类固醇为 93%。对于不需要机械通气但需要补充氧气的患者,瑞德西韦的死亡率绝对降低≥1%的概率为 81%,地塞米松为 93%。最后,对于不需要氧气支持的患者,瑞德西韦的死亡率绝对降低≥1%的概率为 29%,地塞米松为 4%。

结论和相关性

使用贝叶斯分析方法,瑞德西韦除了需要补充氧气但不需要机械通气的患者外,降低死亡率的可能性较低。皮质类固醇对需要氧气支持的患者更有希望,尤其是需要机械通气的患者。在等待更明确的研究结果的同时,这种对证据的概率解释将有助于指导临床医生的治疗决策,以及指南和政策制定者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8a/7849442/60ee725720e2/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验